NASDAQ:XGN Exagen (XGN) Stock Price, News & Analysis $3.72 +0.23 (+6.59%) As of 03:34 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Exagen Stock (NASDAQ:XGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Exagen alerts:Sign Up Key Stats Today's Range$3.30▼$3.8450-Day Range$2.65▼$3.9852-Week Range$2.59▼$12.23Volume450,603 shsAverage Volume450,522 shsMarket Capitalization$89.88 millionP/E RatioN/ADividend YieldN/APrice Target$9.25Consensus RatingModerate Buy Company Overview Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders. The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel. These tests combine proprietary immunoassay technology with algorithm-driven analysis to deliver more precise and actionable diagnostic insights. All assays are performed in Exagen’s CLIA-certified, CAP-accredited laboratory to ensure consistent quality and reliability. Exagen works closely with rheumatologists, immunologists and other healthcare providers across the United States, and is pursuing strategic partnerships to extend its reach into European markets. By filling critical gaps in standard autoimmune testing, the company aims to support earlier diagnosis, guide treatment decisions and improve long-term patient outcomes. The company is led by President and Chief Executive Officer Stephen Heyser, whose background spans diagnostics, biotech and laboratory services. Under his leadership, Exagen continues to invest in research and development to enhance its existing testing platform and explore new assay applications within the autoimmune space.AI Generated. May Contain Errors. Read More Exagen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreXGN MarketRank™: Exagen scored higher than 82% of companies evaluated by MarketBeat, and ranked 112th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingExagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialExagen has a consensus price target of $9.25, representing about 152.7% upside from its current price of $3.66.Amount of Analyst CoverageExagen has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exagen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exagen are expected to grow in the coming year, from ($0.68) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exagen is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exagen is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExagen has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exagen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.43% of the float of Exagen has been sold short.Short Interest Ratio / Days to CoverExagen has a short interest ratio ("days to cover") of 3.87, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exagen has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExagen does not currently pay a dividend.Dividend GrowthExagen does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.32 News SentimentExagen has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Exagen this week, compared to 3 articles on an average week.Search Interest5 people have searched for XGN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows1 people have added Exagen to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,089.00 in company stock.Percentage Held by Insiders12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exagen's insider trading history. Receive XGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XGN Stock News HeadlinesExagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 19 at 2:07 AM | americanbankingnews.comExagen Earnings Call Highlights Growth Amid Key RisksMay 15, 2026 | theglobeandmail.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 19 at 1:00 AM | Profits Run (Ad)The Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 15, 2026 | finance.yahoo.comExagen (NASDAQ:XGN) Given New $8.00 Price Target at BTIG ResearchMay 13, 2026 | americanbankingnews.comExagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...May 12, 2026 | finance.yahoo.comExagen Inc. (XGN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRecord revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing lossesMay 12, 2026 | msn.comSee More Headlines XGN Stock Analysis - Frequently Asked Questions How have XGN shares performed this year? Exagen's stock was trading at $6.08 at the beginning of the year. Since then, XGN stock has decreased by 39.8% and is now trading at $3.66. How were Exagen's earnings last quarter? Exagen Inc. (NASDAQ:XGN) posted its quarterly earnings data on Monday, May, 11th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.07. The company had revenue of $17.31 million for the quarter, compared to analysts' expectations of $16.41 million. Exagen had a negative trailing twelve-month return on equity of 94.37% and a negative net margin of 29.49%. Read the conference call transcript. When did Exagen IPO? Exagen (XGN) raised $54 million in an initial public offering on Thursday, September 19th 2019. The company issued 3,600,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO. Who are Exagen's major shareholders? Top institutional investors of Exagen include FourWorld Capital Management LLC (1.82%), Sei Investments Co. (1.01%), Renaissance Technologies LLC (0.84%) and Perkins Capital Management Inc. (0.30%). Insiders that own company stock include Nmsic Co-Investment Fund, LP, James L L Tullis, John Aballi and Kamal Adawi. View institutional ownership trends. How do I buy shares of Exagen? Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exagen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), CNX Resources (CNX) and Ford Motor (F). Company Calendar Last Earnings5/11/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 XGN's financial health is in the Red zone, according to TradeSmith. XGN has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryHealthcare Current SymbolNASDAQ:XGN CIK1274737 Webwww.exagen.com Phone760-560-1501FaxN/AEmployees220Year Founded2002Price Target and Rating Average Price Target for Exagen$9.25 High Price Target$10.00 Low Price Target$8.00 Potential Upside/Downside+148.7%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.95 million Net Margins-29.49% Pretax Margin-29.36% Return on Equity-94.37% Return on Assets-28.96% Debt Debt-to-Equity Ratio1.67 Current Ratio3.47 Quick Ratio3.47 Sales & Book Value Annual Sales$66.57 million Price / Sales1.35 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book4.83Miscellaneous Outstanding Shares24,160,000Free Float21,116,000Market Cap$89.88 million OptionableOptionable Beta1.81 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:XGN) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exagen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
